Astellas To Jointly Develop And Market FD Drug With Zeria
This article was originally published in PharmAsia News
Astellas Pharma and Zeria Pharmaceutical, both based in Tokyo, will co-develop and co-market functional dyspepsia agent Z-338/YM443. Based on the agreement, Zeria will obtain marketing approval in Japan, and both companies will co-market the product under the single brand name. Discovered by Zeria, Z-338/YM443 inhibits peripheral acetylcholinesterase activities, resulting in improvement of delayed gastric emptying, a symptom of FD. Astellas also has obtained exclusive development and marketing rights in North America for Z-338/YM443 and a Phase II trial is underway. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.